Who are Sorafenib+Pazopanib's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sorafenib + Pravastatin, Sorafenib Ramp-Up Regimen, Sorafenib (SORA), Sorafenib Standard Dosing Regimen, Sorafenib (SOR), TACE plus sorafenib.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sorafenib-pazopanib.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Sorafenib+Pazopanib — Competitive Intelligence Brief

Sorafenib+Pazopanib (Sorafenib+Pazopanib) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: multi-kinase inhibitor. Area: Oncology.

phase 3 multi-kinase inhibitor RAF, VEGFR, PDGFR Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Sorafenib+Pazopanib (Sorafenib+Pazopanib) — Technical University of Munich. Sorafenib and Pazopanib are multi-kinase inhibitors that target various pathways involved in tumor growth and angiogenesis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Sorafenib+Pazopanib TARGET	Sorafenib+Pazopanib	Technical University of Munich	phase 3	multi-kinase inhibitor	RAF, VEGFR, PDGFR
Sorafenib + Pravastatin	Sorafenib + Pravastatin	Centre Hospitalier Universitaire Dijon	phase 3	Multi-kinase inhibitor + HMG-CoA reductase inhibitor	RAF, VEGFR, PDGFR (sorafenib); HMG-CoA reductase (pravastatin)
Sorafenib Ramp-Up Regimen	Sorafenib Ramp-Up Regimen	University of Florida	marketed	Multi-kinase inhibitor	BRAF, VEGFR-2, VEGFR-3, PDGFR-β, FLT-3, c-KIT
Sorafenib (SORA)	Sorafenib (SORA)	Nanfang Hospital, Southern Medical University	marketed	Multi-kinase inhibitor	RAF, VEGFR-2, VEGFR-3, PDGFR-β
Sorafenib Standard Dosing Regimen	Sorafenib Standard Dosing Regimen	University of Florida	marketed	Multi-kinase inhibitor	BRAF, VEGFR-2, VEGFR-3, PDGFR-β, FLT-3, c-KIT
Sorafenib (SOR)	Sorafenib (SOR)	The University of Texas Health Science Center at San Antonio	marketed	Multi-kinase inhibitor; RAF/VEGFR/PDGFR inhibitor	RAF, VEGFR-2, VEGFR-3, PDGFR-β, FLT-3, c-KIT
TACE plus sorafenib	TACE plus sorafenib	Guangxi Medical University	phase 3	Combination therapy (locoregional procedure + multi-kinase inhibitor)	VEGFR, PDGFR, RAF kinases (sorafenib component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (multi-kinase inhibitor class)

Beijing Shenogen Biomedical Co., Ltd · 1 drug in this class
Technical University of Munich · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sorafenib+Pazopanib — Competitive Intelligence Brief. https://druglandscape.com/ci/sorafenib-pazopanib. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab